Next Generation Sequencing CLIA Laboratory Services Market by Service Type (Clinical Exome Sequencing, Targeted Gene Panel Testing, Whole Genome Sequencing), Application (Infectious Disease, Inherited Disease, Oncology), End User, Technology Platform, Sam
Description
The Next Generation Sequencing CLIA Laboratory Services Market was valued at USD 6.78 billion in 2024 and is projected to grow to USD 7.71 billion in 2025, with a CAGR of 13.89%, reaching USD 19.21 billion by 2032.
Comprehensive introduction to the evolving role of CLIA-certified next-gen sequencing laboratories in clinical diagnostics research and integrated patient care
Next generation sequencing performed in CLIA-certified laboratories has transitioned from a niche capability to a foundational element of modern clinical diagnostics and translational research. This introduction outlines the defining characteristics of CLIA laboratory services for sequencing: rigorous quality systems, validated workflows, and a continuous emphasis on analytical and clinical validity. Laboratories operating under CLIA oversight balance clinical utility with operational scalability, managing complex supply chains, instrument qualification, and evolving regulatory expectations while delivering patient-facing and research outputs.
Over the past decade, the convergence of higher throughput sequencing, standardized bioinformatics pipelines, and expanded clinical indications has altered how laboratories position services. Clinical exome testing, targeted gene panels, and whole genome sequencing each require distinct validation strategies and reporting frameworks, and each must align with laboratory information management systems and clinical decision support. As a consequence, laboratory leadership must coordinate cross-functional teams that include molecular technologists, bioinformaticians, and compliance specialists to maintain turn-around-time targets while ensuring reproducible results.
Importantly, the clinical environment now demands greater interoperability with electronic health records and an emphasis on scalable data governance. In this context, CLIA laboratories are adopting modular workflows and vendor-agnostic approaches that permit rapid adoption of new assays and technologies without compromising regulatory compliance, thereby enabling a sustainable pathway from innovation to routine clinical use.
Detailed analysis of technological regulatory and clinical paradigm shifts reshaping CLIA laboratory services and diagnostic approaches across care settings
The landscape of CLIA next generation sequencing laboratory services is being reshaped by an array of interdependent shifts that span technology, regulation, and clinical practice. Technological advances, including improvements in throughput, chemistry, and sample preparation automation, are enabling laboratories to expand test menus while reducing manual intervention. Simultaneously, the maturation of bioinformatics and variant interpretation tools is raising expectations for standardized reporting, actionable outputs, and explainable algorithms.
Regulatory dynamics are exerting a parallel influence. Policymakers and accreditation bodies are emphasizing transparency of analytical validation and post-market performance monitoring, which is prompting laboratories to invest in robust quality management systems and external proficiency testing. Reimbursement environments are also changing, with payers requiring clearer evidence of clinical utility and cost-effectiveness before expanding coverage for complex genomic tests.
Clinically, precision medicine initiatives are driving demand for integrated testing strategies that combine targeted panels, exome, or whole genome sequencing with pharmacogenomic and infectious disease assays. In addition, care models are decentralizing: hospitals, reference diagnostic laboratories, and direct-to-consumer channels are redefining how samples are collected and routed. Consequently, laboratory leaders must navigate these transformative shifts by aligning investments in automation, informatics, and quality processes with evolving clinical pathways and payer expectations.
In-depth evaluation of how United States tariff shifts in 2025 influence supply chains reagent availability sequencing platform procurement and lab operations
The implementation of new tariffs in the United States in 2025 has introduced tangible pressure across the sequencing supply chain, with cumulative effects on equipment procurement, reagent sourcing, and consumables logistics. Because many sequencing platforms and critical reagents are manufactured or assembled overseas, tariff-related cost adjustments increase the total landed cost of instruments and consumable portfolios. Laboratories that operate on thin margin structures or that maintain tight procurement cycles may experience elevated unit costs and extended negotiation timelines.
Beyond direct cost implications, tariffs amplify vulnerabilities within inventory and vendor management. Purchasing strategies that previously relied on just-in-time deliveries now require contingency buffers, alternate sourcing, and contractual protections to ensure continuity of testing services. In turn, platform selection decisions are increasingly influenced by the geographic footprint of manufacturers, the local availability of spare parts, and the flexibility of service contracts.
Operationally, laboratories must respond through a mix of tactical and strategic measures. Short-term actions include renegotiating supply agreements, consolidating orders to achieve scale discounts, and prioritizing assays by clinical urgency. Over the medium term, organizations may pursue diversification across technology platforms and regional suppliers to reduce exposure, invest in on-site inventory management systems to anticipate disruptions, and engage proactively with procurement and finance to model tariff impacts on service delivery. These cumulative effects underscore the need for supply chain resilience as a core laboratory capability.
Integrated segmentation insights linking service type application end user technology platform and sample type to clinical utility and laboratory strategy
Segmentation matters because each axis-service type, application, end user, technology platform, and sample type-carries distinct validation requirements, operational workflows, and clinical value propositions. When considering service type, clinical exome sequencing must be split into adult and pediatric exome workflows, given differences in diagnostic yield and consent frameworks; targeted gene panel testing covers cancer panels, cardiovascular panels, and neurological disorder panels, with cancer panels further differentiated into hematologic and solid tumor panels; whole genome sequencing introduces separate data management and reporting complexities that drive informatics investment.
From an application perspective, infectious disease testing is bifurcated into bacterial and viral workflows that demand divergent sample preparation and contamination control, while inherited disease analysis requires attention to both common and rare disease variant interpretation. Oncology applications separate hematologic malignancies from solid tumor analyses due to tumor fraction considerations and sample sources, and reproductive health tests span noninvasive prenatal testing and preimplantation genetic testing, each with unique counseling and regulatory touchpoints.
End users vary from diagnostic laboratories and direct-to-consumer testing channels to hospitals, clinics, and research institutes, each imposing different service-level expectations, turnaround time constraints, and reporting formats. Technology platform choice-whether BGI platforms such as Bgiseq 500 and Mgiseq, Illumina options like MiSeq NextSeq or NovaSeq, or Thermo Fisher systems such as Ion Torrent PGM and Ion Torrent Proton-shapes throughput, per-sample economics, and compatibility with assay chemistries. Finally, sample type-blood including plasma and whole blood, saliva, and tissue with FFPE or fresh frozen preservation-determines extraction workflows and affects analytical sensitivity. Taken together, these segmentation layers guide laboratory strategy, capacity planning, and regulatory approach in nuanced and actionable ways.
Regional analysis across Americas EMEA and Asia-Pacific showing how local regulatory and infrastructure dynamics shape clinical adoption of next-gen sequencing
Regional dynamics exert a powerful influence on how CLIA next generation sequencing services are structured and delivered. In the Americas, mature reimbursement frameworks, an established network of reference laboratories, and strong clinical trial activity support rapid adoption of complex assays, yet this region also faces concentrated supply chain risks tied to global manufacturing hubs. In Europe Middle East & Africa, heterogeneous regulatory regimes and variable reimbursement policies create a mosaic of market entry considerations, prompting laboratories and vendors to pursue region-specific validations and partnerships that address local standards and stakeholder needs.
In Asia-Pacific, adoption is accelerated by integrated public health initiatives and large-scale population genomics programs, but differences in data privacy regimes and laboratory accreditation processes necessitate tailored compliance strategies. Cross-region differences in clinical guidelines, workforce availability, and infrastructure maturity influence the practical feasibility of deploying high-throughput platforms versus targeted services. Consequently, laboratories seeking to expand internationally must craft differentiated operating models that account for localization requirements, logistics complexity, and strategic partnership opportunities in each region.
Corporate insights into sequencing platform providers reagent suppliers clinical lab networks and service integrators shaping innovation and market position
Companies operating within the CLIA sequencing ecosystem are advancing along multiple strategic vectors including platform innovation, reagent portfolio expansion, informatics integration, and end-to-end service offerings. Platform providers invest in chemistry and instrument automation to lower hands-on time and increase throughput, while reagent manufacturers optimize kit formats for ease of validation and supply chain robustness. Clinical laboratory networks and large hospital systems focus on integrating sequencing outputs into care pathways and electronic health records, enhancing the actionable value of genomic insights.
Service integrators and specialized testing laboratories emphasize validated workflows and scalable quality systems to meet regulatory expectations and payer scrutiny. Across these groups, differentiation increasingly rests on informatics maturity: standardized pipelines, variant interpretation frameworks, and reporting interfaces that facilitate clinician uptake. Strategic partnerships and distribution agreements are common tactics for expanding geographic reach, while investment in customer support, training, and proficiency programs strengthens long-term adoption. For organizations evaluating partnerships or vendor selection, attention to long-term serviceability, software upgrade policies, and alignment of roadmaps with clinical priorities is essential.
Actionable recommendations for laboratory leaders technology partners and health systems to prioritize adoption streamline workflows and strengthen compliance
Laboratory leaders and technology partners should pursue a set of prioritized, actionable steps to strengthen competitiveness and operational resilience. First, diversify supplier relationships and maintain critical safety-stock to mitigate tariff-induced or geopolitical disruptions. Second, adopt a multi-platform strategy where feasible, combining high-throughput systems with targeted benchtop instruments to balance cost and flexibility. Third, invest in automation and standardized pre-analytic workflows to reduce variability and accelerate throughput while maintaining CLIA compliance.
Additionally, enhance informatics and variant interpretation capabilities by deploying validated pipelines and investing in clinical decision support that improves report clarity for ordering physicians. Engage proactively with payers and clinicians to build evidence packages that demonstrate clinical utility and cost-effectiveness, thereby smoothing reimbursement pathways. Strengthen workforce development through cross-training initiatives that create flexible staffing models across molecular and bioinformatics functions. Finally, integrate supply chain analytics and scenario planning into governance routines so that procurement, finance, and laboratory operations can respond rapidly to disruptions and evolving regulatory requirements.
Clear research methodology outlining primary data collection stakeholder interviews technology assessment and validation steps that underpin analytical rigor
This study applied a mixed-methods research approach to ensure robust, verifiable findings. Primary data collection included structured interviews with laboratory directors, procurement leads, and technology vendors, supplemented by targeted consultations with clinical end users and regulatory experts. Secondary sources encompassed peer-reviewed literature, regulatory guidance documents, and vendor technical specifications, which provided context for technology assessment and validation considerations. Cross-validation occurred through triangulation across data sources and iterative review by subject matter experts.
Technology evaluations assessed platform throughput, chemistry compatibility, and serviceability, while supply chain analysis mapped vendor footprints, logistics pathways, and contingency options. Regulatory mapping identified accreditation and reporting requirements across jurisdictions. Validation steps included review of analytical performance claims, assay workflow documentation, and reproducibility checks described by participating laboratories. Together, these methodological elements underpin the analysis and provide transparency for readers seeking to understand how conclusions were reached.
Targeted conclusion outlining key takeaways principal risks and immediate actions for laboratory leaders vendors and healthcare leaders in NGS operations
The cumulative analysis synthesizes operational, technological, regulatory, and commercial observations into a clear set of strategic priorities for stakeholders in CLIA next generation sequencing services. Key takeaways emphasize the importance of supply chain resilience, platform diversification, informatics maturity, and proactive payer engagement. Risk considerations include tariff-related cost pressures, regulatory variability across regions, and workforce constraints that can impede scale-up. These risks can be mitigated through deliberate procurement strategies, targeted investments in automation and bioinformatics, and focused clinical evidence generation.
Near-term actions for laboratory leaders include validating cross-platform workflows to preserve flexibility, strengthening inventory controls, and enhancing clinical reporting to drive adoption. For vendors and integrators, aligning roadmaps with laboratory needs for serviceability, assay compatibility, and informatics interoperability will accelerate uptake. Collectively, these measures support a resilient, scalable approach to delivering clinically meaningful sequencing services while navigating evolving policy and market dynamics in the NGS landscape.
Note: PDF & Excel + Online Access - 1 Year
Comprehensive introduction to the evolving role of CLIA-certified next-gen sequencing laboratories in clinical diagnostics research and integrated patient care
Next generation sequencing performed in CLIA-certified laboratories has transitioned from a niche capability to a foundational element of modern clinical diagnostics and translational research. This introduction outlines the defining characteristics of CLIA laboratory services for sequencing: rigorous quality systems, validated workflows, and a continuous emphasis on analytical and clinical validity. Laboratories operating under CLIA oversight balance clinical utility with operational scalability, managing complex supply chains, instrument qualification, and evolving regulatory expectations while delivering patient-facing and research outputs.
Over the past decade, the convergence of higher throughput sequencing, standardized bioinformatics pipelines, and expanded clinical indications has altered how laboratories position services. Clinical exome testing, targeted gene panels, and whole genome sequencing each require distinct validation strategies and reporting frameworks, and each must align with laboratory information management systems and clinical decision support. As a consequence, laboratory leadership must coordinate cross-functional teams that include molecular technologists, bioinformaticians, and compliance specialists to maintain turn-around-time targets while ensuring reproducible results.
Importantly, the clinical environment now demands greater interoperability with electronic health records and an emphasis on scalable data governance. In this context, CLIA laboratories are adopting modular workflows and vendor-agnostic approaches that permit rapid adoption of new assays and technologies without compromising regulatory compliance, thereby enabling a sustainable pathway from innovation to routine clinical use.
Detailed analysis of technological regulatory and clinical paradigm shifts reshaping CLIA laboratory services and diagnostic approaches across care settings
The landscape of CLIA next generation sequencing laboratory services is being reshaped by an array of interdependent shifts that span technology, regulation, and clinical practice. Technological advances, including improvements in throughput, chemistry, and sample preparation automation, are enabling laboratories to expand test menus while reducing manual intervention. Simultaneously, the maturation of bioinformatics and variant interpretation tools is raising expectations for standardized reporting, actionable outputs, and explainable algorithms.
Regulatory dynamics are exerting a parallel influence. Policymakers and accreditation bodies are emphasizing transparency of analytical validation and post-market performance monitoring, which is prompting laboratories to invest in robust quality management systems and external proficiency testing. Reimbursement environments are also changing, with payers requiring clearer evidence of clinical utility and cost-effectiveness before expanding coverage for complex genomic tests.
Clinically, precision medicine initiatives are driving demand for integrated testing strategies that combine targeted panels, exome, or whole genome sequencing with pharmacogenomic and infectious disease assays. In addition, care models are decentralizing: hospitals, reference diagnostic laboratories, and direct-to-consumer channels are redefining how samples are collected and routed. Consequently, laboratory leaders must navigate these transformative shifts by aligning investments in automation, informatics, and quality processes with evolving clinical pathways and payer expectations.
In-depth evaluation of how United States tariff shifts in 2025 influence supply chains reagent availability sequencing platform procurement and lab operations
The implementation of new tariffs in the United States in 2025 has introduced tangible pressure across the sequencing supply chain, with cumulative effects on equipment procurement, reagent sourcing, and consumables logistics. Because many sequencing platforms and critical reagents are manufactured or assembled overseas, tariff-related cost adjustments increase the total landed cost of instruments and consumable portfolios. Laboratories that operate on thin margin structures or that maintain tight procurement cycles may experience elevated unit costs and extended negotiation timelines.
Beyond direct cost implications, tariffs amplify vulnerabilities within inventory and vendor management. Purchasing strategies that previously relied on just-in-time deliveries now require contingency buffers, alternate sourcing, and contractual protections to ensure continuity of testing services. In turn, platform selection decisions are increasingly influenced by the geographic footprint of manufacturers, the local availability of spare parts, and the flexibility of service contracts.
Operationally, laboratories must respond through a mix of tactical and strategic measures. Short-term actions include renegotiating supply agreements, consolidating orders to achieve scale discounts, and prioritizing assays by clinical urgency. Over the medium term, organizations may pursue diversification across technology platforms and regional suppliers to reduce exposure, invest in on-site inventory management systems to anticipate disruptions, and engage proactively with procurement and finance to model tariff impacts on service delivery. These cumulative effects underscore the need for supply chain resilience as a core laboratory capability.
Integrated segmentation insights linking service type application end user technology platform and sample type to clinical utility and laboratory strategy
Segmentation matters because each axis-service type, application, end user, technology platform, and sample type-carries distinct validation requirements, operational workflows, and clinical value propositions. When considering service type, clinical exome sequencing must be split into adult and pediatric exome workflows, given differences in diagnostic yield and consent frameworks; targeted gene panel testing covers cancer panels, cardiovascular panels, and neurological disorder panels, with cancer panels further differentiated into hematologic and solid tumor panels; whole genome sequencing introduces separate data management and reporting complexities that drive informatics investment.
From an application perspective, infectious disease testing is bifurcated into bacterial and viral workflows that demand divergent sample preparation and contamination control, while inherited disease analysis requires attention to both common and rare disease variant interpretation. Oncology applications separate hematologic malignancies from solid tumor analyses due to tumor fraction considerations and sample sources, and reproductive health tests span noninvasive prenatal testing and preimplantation genetic testing, each with unique counseling and regulatory touchpoints.
End users vary from diagnostic laboratories and direct-to-consumer testing channels to hospitals, clinics, and research institutes, each imposing different service-level expectations, turnaround time constraints, and reporting formats. Technology platform choice-whether BGI platforms such as Bgiseq 500 and Mgiseq, Illumina options like MiSeq NextSeq or NovaSeq, or Thermo Fisher systems such as Ion Torrent PGM and Ion Torrent Proton-shapes throughput, per-sample economics, and compatibility with assay chemistries. Finally, sample type-blood including plasma and whole blood, saliva, and tissue with FFPE or fresh frozen preservation-determines extraction workflows and affects analytical sensitivity. Taken together, these segmentation layers guide laboratory strategy, capacity planning, and regulatory approach in nuanced and actionable ways.
Regional analysis across Americas EMEA and Asia-Pacific showing how local regulatory and infrastructure dynamics shape clinical adoption of next-gen sequencing
Regional dynamics exert a powerful influence on how CLIA next generation sequencing services are structured and delivered. In the Americas, mature reimbursement frameworks, an established network of reference laboratories, and strong clinical trial activity support rapid adoption of complex assays, yet this region also faces concentrated supply chain risks tied to global manufacturing hubs. In Europe Middle East & Africa, heterogeneous regulatory regimes and variable reimbursement policies create a mosaic of market entry considerations, prompting laboratories and vendors to pursue region-specific validations and partnerships that address local standards and stakeholder needs.
In Asia-Pacific, adoption is accelerated by integrated public health initiatives and large-scale population genomics programs, but differences in data privacy regimes and laboratory accreditation processes necessitate tailored compliance strategies. Cross-region differences in clinical guidelines, workforce availability, and infrastructure maturity influence the practical feasibility of deploying high-throughput platforms versus targeted services. Consequently, laboratories seeking to expand internationally must craft differentiated operating models that account for localization requirements, logistics complexity, and strategic partnership opportunities in each region.
Corporate insights into sequencing platform providers reagent suppliers clinical lab networks and service integrators shaping innovation and market position
Companies operating within the CLIA sequencing ecosystem are advancing along multiple strategic vectors including platform innovation, reagent portfolio expansion, informatics integration, and end-to-end service offerings. Platform providers invest in chemistry and instrument automation to lower hands-on time and increase throughput, while reagent manufacturers optimize kit formats for ease of validation and supply chain robustness. Clinical laboratory networks and large hospital systems focus on integrating sequencing outputs into care pathways and electronic health records, enhancing the actionable value of genomic insights.
Service integrators and specialized testing laboratories emphasize validated workflows and scalable quality systems to meet regulatory expectations and payer scrutiny. Across these groups, differentiation increasingly rests on informatics maturity: standardized pipelines, variant interpretation frameworks, and reporting interfaces that facilitate clinician uptake. Strategic partnerships and distribution agreements are common tactics for expanding geographic reach, while investment in customer support, training, and proficiency programs strengthens long-term adoption. For organizations evaluating partnerships or vendor selection, attention to long-term serviceability, software upgrade policies, and alignment of roadmaps with clinical priorities is essential.
Actionable recommendations for laboratory leaders technology partners and health systems to prioritize adoption streamline workflows and strengthen compliance
Laboratory leaders and technology partners should pursue a set of prioritized, actionable steps to strengthen competitiveness and operational resilience. First, diversify supplier relationships and maintain critical safety-stock to mitigate tariff-induced or geopolitical disruptions. Second, adopt a multi-platform strategy where feasible, combining high-throughput systems with targeted benchtop instruments to balance cost and flexibility. Third, invest in automation and standardized pre-analytic workflows to reduce variability and accelerate throughput while maintaining CLIA compliance.
Additionally, enhance informatics and variant interpretation capabilities by deploying validated pipelines and investing in clinical decision support that improves report clarity for ordering physicians. Engage proactively with payers and clinicians to build evidence packages that demonstrate clinical utility and cost-effectiveness, thereby smoothing reimbursement pathways. Strengthen workforce development through cross-training initiatives that create flexible staffing models across molecular and bioinformatics functions. Finally, integrate supply chain analytics and scenario planning into governance routines so that procurement, finance, and laboratory operations can respond rapidly to disruptions and evolving regulatory requirements.
Clear research methodology outlining primary data collection stakeholder interviews technology assessment and validation steps that underpin analytical rigor
This study applied a mixed-methods research approach to ensure robust, verifiable findings. Primary data collection included structured interviews with laboratory directors, procurement leads, and technology vendors, supplemented by targeted consultations with clinical end users and regulatory experts. Secondary sources encompassed peer-reviewed literature, regulatory guidance documents, and vendor technical specifications, which provided context for technology assessment and validation considerations. Cross-validation occurred through triangulation across data sources and iterative review by subject matter experts.
Technology evaluations assessed platform throughput, chemistry compatibility, and serviceability, while supply chain analysis mapped vendor footprints, logistics pathways, and contingency options. Regulatory mapping identified accreditation and reporting requirements across jurisdictions. Validation steps included review of analytical performance claims, assay workflow documentation, and reproducibility checks described by participating laboratories. Together, these methodological elements underpin the analysis and provide transparency for readers seeking to understand how conclusions were reached.
Targeted conclusion outlining key takeaways principal risks and immediate actions for laboratory leaders vendors and healthcare leaders in NGS operations
The cumulative analysis synthesizes operational, technological, regulatory, and commercial observations into a clear set of strategic priorities for stakeholders in CLIA next generation sequencing services. Key takeaways emphasize the importance of supply chain resilience, platform diversification, informatics maturity, and proactive payer engagement. Risk considerations include tariff-related cost pressures, regulatory variability across regions, and workforce constraints that can impede scale-up. These risks can be mitigated through deliberate procurement strategies, targeted investments in automation and bioinformatics, and focused clinical evidence generation.
Near-term actions for laboratory leaders include validating cross-platform workflows to preserve flexibility, strengthening inventory controls, and enhancing clinical reporting to drive adoption. For vendors and integrators, aligning roadmaps with laboratory needs for serviceability, assay compatibility, and informatics interoperability will accelerate uptake. Collectively, these measures support a resilient, scalable approach to delivering clinically meaningful sequencing services while navigating evolving policy and market dynamics in the NGS landscape.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
185 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of automation and AI-driven bioinformatics pipelines for high throughput clinical sequencing
- 5.2. Expansion of liquid biopsy-based NGS assays for real-time monitoring of minimal residual disease in oncology
- 5.3. Implementation of pharmacogenomic NGS testing for personalized medication therapy management in diverse populations
- 5.4. Adoption of long-read sequencing technologies to improve detection of structural variants in genetic disease diagnostics
- 5.5. Development of rapid sample-to-report NGS workflows to support urgent infectious disease outbreak response
- 5.6. Standardization of CLIA-compliant reference materials and proficiency testing for NGS assay validation across labs
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Next Generation Sequencing CLIA Laboratory Services Market, by Service Type
- 8.1. Clinical Exome Sequencing
- 8.1.1. Adult Exome
- 8.1.2. Pediatric Exome
- 8.2. Targeted Gene Panel Testing
- 8.2.1. Cancer Panels
- 8.2.1.1. Hematologic Panels
- 8.2.1.2. Solid Tumor Panels
- 8.2.2. Cardiovascular Panels
- 8.2.3. Neurological Disorder Panels
- 8.3. Whole Genome Sequencing
- 9. Next Generation Sequencing CLIA Laboratory Services Market, by Application
- 9.1. Infectious Disease
- 9.1.1. Bacterial Infections
- 9.1.2. Viral Infections
- 9.2. Inherited Disease
- 9.2.1. Common Disease
- 9.2.2. Rare Disease
- 9.3. Oncology
- 9.3.1. Hematologic Malignancies
- 9.3.2. Solid Tumor
- 9.4. Pharmacogenomics
- 9.5. Reproductive Health
- 9.5.1. Noninvasive Prenatal Testing
- 9.5.2. Preimplantation Genetic Testing
- 10. Next Generation Sequencing CLIA Laboratory Services Market, by End User
- 10.1. Diagnostic Laboratories
- 10.2. Direct To Consumer Testing
- 10.3. Hospitals And Clinics
- 10.4. Research Institutes
- 11. Next Generation Sequencing CLIA Laboratory Services Market, by Technology Platform
- 11.1. BGI Sequencing Platforms
- 11.1.1. Bgiseq 500
- 11.1.2. Mgiseq
- 11.2. Illumina Sequencing Platforms
- 11.2.1. MiSeq
- 11.2.2. NextSeq
- 11.2.3. NovaSeq
- 11.3. Thermo Fisher Sequencing Platforms
- 11.3.1. Ion Torrent Pgm
- 11.3.2. Ion Torrent Proton
- 12. Next Generation Sequencing CLIA Laboratory Services Market, by Sample Type
- 12.1. Blood
- 12.1.1. Plasma
- 12.1.2. Whole Blood
- 12.2. Saliva
- 12.3. Tissue
- 12.3.1. Ffpe
- 12.3.2. Fresh Frozen
- 13. Next Generation Sequencing CLIA Laboratory Services Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Next Generation Sequencing CLIA Laboratory Services Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Next Generation Sequencing CLIA Laboratory Services Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Adaptive Biotechnologies Corporation
- 16.3.2. Agilent Technologies Inc
- 16.3.3. ARUP Laboratories
- 16.3.4. Azenta Life Sciences
- 16.3.5. BGI Genomics Co Ltd
- 16.3.6. Bio-Rad Laboratories Inc
- 16.3.7. Charles River Laboratories Inc
- 16.3.8. Eurofins Scientific SE
- 16.3.9. F Hoffmann-La Roche AG
- 16.3.10. Foundation Medicine Inc
- 16.3.11. Fulgent Genetics Inc
- 16.3.12. Guardant Health Inc
- 16.3.13. Illumina Inc
- 16.3.14. Invitae Corporation
- 16.3.15. IQVIA Laboratories
- 16.3.16. Macrogen Inc
- 16.3.17. Myriad Genetics Inc
- 16.3.18. Natera Inc
- 16.3.19. NeoGenomics Laboratories
- 16.3.20. Novogene Corporation
- 16.3.21. Oxford Nanopore Technologies plc
- 16.3.22. Personalis Inc
- 16.3.23. QIAGEN N V
- 16.3.24. Quest Diagnostics Incorporated
- 16.3.25. Thermo Fisher Scientific Inc
- 16.3.26. Veracyte Inc
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
